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The structural genomics effort at the Seattle Structural Genomics Center for
Infectious Disease (SSGCID) requires the manipulation of large numbers of
amino-acid sequences and the underlying DNA sequences which are to be
cloned into expression vectors. To improve efﬁciency in high-throughput protein
structure determination, a database software package, Gene Composer, has
been developed which facilitates the information-rich design of protein
constructs and their underlying gene sequences. With its modular workﬂow
design and numerous graphical user interfaces, Gene Composer enables
researchers to perform all common bioinformatics steps used in modern
structure-guided protein engineering and synthetic gene engineering. An
example of the structure determination of H1N1 RNA-dependent RNA
polymerase PB2 subunit is given.
1. Introduction
The Seattle Structural Genomics Center for Infectious Disease
(SSGCID; http://www.ssgcid.org/home/index.asp) is devoted to the
application of state-of-the-art structural genomics technologies to
structurally characterize targeted proteins from NIAID Category
A–C pathogens and organisms. The goal is to create a collection of
three-dimensional protein structures that are widely available to the
broad scientiﬁc community and serve as a blueprint for structure-
based drug development for infectious diseases. The SSGCID uses an
escalating tier approach to protein production (Fig. 1). The overall
SSGCID structure-determination pipeline involves a number of
activities that are distributed between the Target Selection, Cloning
& Expression Screening, Protein Production, Crystallization and
Data Collection & Structure Solution teams. In order to maximize the
likelihood of success of each target, yet minimize the cost per struc-
ture, we have adopted a multipronged serial escalation approach,
whereby targets initially enter a standard high-throughput bacterial
protein-expression system (Tier 1) and enter more resource-intensive
‘rescue pathways’ (Tiers 2–9) only after failing the initial approach.
Tier 3 uses gene synthesis and multiple construct design as its tech-
nological focus.
To maximize our chances of success, we choose homologues and
orthologues from multiple organisms with the goal of characterizing
multiple examples of targets. It is well established in structural
biology that making multiple different constructs of each target with
various N- and C-terminal deletions or surface substitutions increases
the chance of successfully obtaining soluble crystallizable protein
(Chandonia & Brenner, 2006; Gra ¨slund et al., 2008). Deciding on
where to make deletions and modiﬁcations can be accomplished in
several ways. Making multiple sequence alignments using, for
example, ClustalW (Chenna et al., 2003; Larkin et al., 2007) is
straightforward and can help the researcher decide on conserved
domains. Using secondary-structure information to identify struc-
tured domains can be accomplished by examining the structures of
related entities using software tools such as PyMOL (DeLano, 2002)
or Coot (Emsley & Cowtan, 2004). Creating constructs for cloning
can be accomplished with molecular-biology tools such as Vector NTI
(Invitrogen). Obtaining genomic DNAs from hard-to-obtain species
or from metagenomic projects is difﬁcult if not impossible. In suchcases gene synthesis is the most attractive approach. We have
developed a single computer application called Gene Composer that
incorporates all of these functions into one package. The researcher
can create information-rich multiple sequence alignments incorpor-
ating not only amino-acid sequences but also secondary-structural
information from PDB ﬁles. Individual sequences can then be
extracted from the alignment and used to create a fully codon-
and sequence-engineered synthetic DNA sequence that can be
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Figure 1
The SSGCID structure-determination pipeline. Tiers are represented as columns and described in the text at the bottom of the ﬁgure. Rows show the processes through
which targets pass in each Tier. The numbers indicate how many targets are expected to pass through each step in the pipeline.
Figure 2
Alignment of inﬂuenza A RNA-dependent RNA polymerase PB2 subunit sequences from various inﬂuenza A strains with PDB entry 2vy6 (Guilligay et al., 2008; Tarendeau
et al., 2008).incorporated into a virtual cloning strategy. Vector constructs are
given unique vector-construct identiﬁcations (VCIDs) that are stored
in the database. The VCID database can be queried and the neces-
sary information extracted for each individual clone.
2. Gene Composer software
A typical design cycle starts by deﬁning a desired target protein or
family of targets. We ﬁrst download the relevant target sequences
from the SSGCID central target tracking database (CTTdb). We then
pull in additional information from multiple sources such as FASTA
ﬁles from GenBank (http://www.ncbi.nlm.nih.gov/), structure ﬁles
from the Protein Data Bank (PDB; http://www.rcsb.org/pdb/home/
home.do) or simple text (.txt) ﬁles with homologous sequences of
related proteins or orthologs. Gene Composer automatically creates
the familiar ClustalW (Chenna et al., 2003; Larkin et al., 2007)
multiple sequence alignments, pointing out areas of conservation,
gaps and dissimilar regions. Adding structural information is simple.
Coordinate ﬁles from the PDB of related proteins or domains can be
added to the alignment and used to display experimental information.
Secondary-structural information is annotated and amino acids are
identiﬁed that participate in ligand-binding sites, are water-exposed
or form crystal contacts. At this point the researcher may decide that
it is sufﬁcient to express the activity-bearing domain only or that
multiple amino-acid sequence variants be generated, including N-
and C-terminal truncations, variants with surface mutations and
single or combinations of tags at either end of the protein. Once
domains and constructs have been identiﬁed, the user then deﬁnes
the underlying DNA sequence, either as the native sequence or an
engineered sequence. In the ﬁnal step the user can virtually clone
the constructs into vectors stored in the database using user-deﬁned
adapters and assemblies to create proteins with desired puriﬁcation
tags and features.
2.1. Alignment viewer and construct design
The H1N1 RNA-dependent RNA polymerase subunit PB2 offers
an example of Gene Composer engineering leading to structure
determination. This target has multiple SSGCID identiﬁers of the
form InvaX.07055, where the X refers to multiple different strains
or variants (Table 1). We started with several recent isolates and a
published structure of the inﬂuenza A virus RNA-dependent RNA
polymerase PB2 subunit (PDN entry 2vy6; Guilligay et al., 2008;
Tarendeau et al., 2008) and created the alignment shown in Fig. 2. The
degree of similarity is quite high amongst the SSGCID targets and
2vy6 (Guilligay et al., 2008; Tarendeau et al., 2008). The software not
only extracts the structural information from the PDB but also
displays (i) the chain sequence, which represents the protein put into
crystallization trials, and (ii) the model, which represents the visible
amino acids. In addition to displaying the conservation between
sequences and the secondary structure, we can also interrogate the
PDB ﬁle to extract other structure information such as B factors,
crystal contacts, solvent accessibility and water contacts for any
residue. For example, in Fig. 2 we have highlighted Gln591, which
makes crystal contacts with Gln566, has a B factor of 29.3 A ˚ 2 and
makes two water contacts in the structure.
At this point the researcher can deﬁne a base construct from which
to further design the expressed protein and to begin the gene-design
process. Fig. 3 shows how N- and C-terminal truncations are set by
laboratory communications
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Figure 3
Construct design of InvaB.07055.c.laboratory communications
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Figure 5
Construct Design Viewer. In the lower panel the user can make N- or C-terminal deletions, amino-acid insertions, deletions or surface mutations.
Table 1
PB2 homologues from various species.
The SSGCID targets are named InvaX.07055.a, where X = B (A/Yokohama), C (A/equine), G (A/H1N1) or H (A/chicken). The model 2vy6 is for A/California from an isolate from 1978
(Guilligay et al., 2008; Tarendeau et al., 2008).
SSGCID name Organism ID Reference
InvaB.07055.a A/Yokohama/2017/03 (H3N2) http://www.ncbi.nlm.nih.gov/genomes/FLU/
InvaC.07055.a A/equine/Prague/1/1956 (H7N7) http://www.ncbi.nlm.nih.gov/genomes/FLU/
InvaG.07055.a A/H1N1 subtype http://www.ncbi.nlm.nih.gov/genomes/FLU/
InvaH.07055.a A/chicken/Nanchang/3-120/2001 (H3N2) http://www.ncbi.nlm.nih.gov/genomes/FLU/
2vy6 A/California/10/1978 (H1N1) Tarendeau et al. (2008)
Figure 4
DNA-sequence modiﬁcations available to the user during the gene-design process (Lorimer et al., 2009).inserting a character at the desired end points. Gene Composer then
makes all combinations of truncations.
2.2. Construct Design Viewer
From information such as that displayed in Figs. 2 and 3 the user
can now start to design constructs, making N- and C-terminal dele-
tions, amino-acid insertions/deletions or surface mutations (Figs. 3, 4
and 5). We choose to make truncations at the N- and C-termini or
remove internally disordered loops by simply indicating in the
Construct Design Viewer where the N- and C-termini should be by
right-clicking at the position to start or stop (Fig. 3). To remove an
internal sequence we simply highlight the residues to delete, right
click and chose ‘delete residues’ from the list of options. Multiple
combinations of truncations, mutations, insertion and deletions can
be speciﬁed and all combinations are generated by the program.
2.3. Gene Design Module
The features of the Gene Design Module have been presented in
detail elsewhere (Lorimer et al., 2009), so we will only brieﬂy discuss
them here. Once the user has deﬁned the base construct to be made,
he or she must now deﬁne a DNA sequence for use in the virtual
cloning steps. The user can choose to use the natural sequence as
found, for example, in GenBank or the PDB. Alternatively, the user
may choose to design a gene from scratch by back-translating the
target protein sequence using a codon-usage table (CUT) deﬁned for
the expression host. The CUT tables deﬁne the frequency of codon
occurrence in the host genes, allowing the user to match the gene-
codon frequencies to that of the host’s preferred codons and there-
fore avoid rare codons. Table 2 shows an example of the Escherichia
coli codon-usage table. Gene Composer comes pre-loaded with CUTs
for mammalian, insect cell/baculovirus, E. coli and combined E. coli/
baculovirus genes. Once the basic back-translated gene has been
designed, we can choose to introduce or remove restriction-enzyme
sites, remove cryptic Shine–Dalgarno sequences, remove repeated
sequences, introduce out-of-frame stop codons etc. (Fig. 4; Lorimer et
al., 2009).
Once all constructs have been decided on and the underlying DNA
sequence has been deﬁned the user can now perform a virtual cloning
step in which the gene sequence is inserted, in silico, into a vector
sequence (Fig. 6). The user can import vectors from commercial
sources or create their own vectors. The user deﬁnes the potential
cloning sites, vector-encoded tags, starts and stops. The user can also
deﬁne adapters such as restriction-enzyme recognition sequences as
well as tags and other types of features to be added to the target gene.
These adapters are entered as DNA sequences and can be added to
the ends of coding sequences as desired. These features are color-
coded for easy visualization of the ﬁnal construct-vector map.
Adapters can be concatenated into assemblies that are stored for easy
use. Once a gene sequence has been virtually cloned and stored in the
database itis given a unique identiﬁer called a Vector Construct ID or
VCID. Once created, a VCID cannot be altered in any way so as to
protect the integrity of the database. Deletion of VCIDs is password-
protected to prevent accidental loss of data. Since the VCID is a
software-generated piece of code, users can freely use it as a secure
identiﬁer in communication between parties.
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Figure 6
Virtual cloning in Gene Composer. Once contructs have been created as shown in Fig. 5 they can be virtually cloned. The vector is chosen from a pull-down menu and the
appropriate adapters added to facilitate the cloning strategy. In this example a stop codon has been added to the end of all the constructs and BamHI and HindIII adapters
have been added.3. Conclusions
Structural genomics efforts are becoming commonplace in the ﬁeld of
functional and structural biology. For example, there are currently 36
centers tracked in the Protein Data Bank, including sites in the US,
Japan and Europe. As of July 2011 these centers have submitted
10 370 structures to the PDB. At present the SSGCID is the eighth
most productive center tracked. A key to our success is the ability to
clone, express, purify and crystallize multiple versions of any single
target in our pipeline. The SSGCID uses an escalating-tier approach
to protein production (Fig. 1). Tier 3 uses gene synthesis and multiple
construct design as its technology. As such, in Tier 3 Gene Composer
provides an excellent tool for performing rational construct design
using parameters such as sequence homology, synthetic DNA engi-
neering and structural features. Examples of Tier 3 rescue are
discussed in Raymond et al. (2011). For the example given here of
the H1N1 RNA-dependent RNA polymerase subunit PB2, speciﬁc
DNAs were difﬁcult if not impossible to obtain for this work and
therefore gene synthesis was the only option. Multiple versions of the
protein were created and expression and puriﬁcation were accom-
plished (Raymond et al., 2011; Yamada et al., 2010). Puriﬁed protein
entered into crystallization trials and a structure model was deter-
mined (Fig. 7). The structure and its impact on our understanding of
cross-species transmission are discussed elsewhere (Yamada et al.,
2010).
4. Availability and requirements
Gene Composer software can be downloaded for free from http://
www.genecomposer.net by following a simple click-through regis-
tration license. The operating system required is Windows 2000/XP
and the hardware is a Pentium 4 or Athlon at 1 Ghz with 1 GB RAM.
Gene Composer is a registered trademark of Emerald BioStructures
Inc.
The authors wish the thank all of the members of the SSGCID
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Table 2
E. coli codon-usage table (CUT).
The indicated values represent the fractional occurrence of each codon in the E. coli
transcriptome. Data from Kazusa (http://www.kazusa.or.jp/codon/).
Codon Amino acid Frequency
TTT Phe 0.21
TTC Phe 0.79
TTA Leu 0.03
TTG Leu 0.02
TCT Ser 0.39
TCC Ser 0.39
TCA Ser 0.02
TCG Ser 0.04
TAT Tyr 0.20
TAC Tyr 0.80
TAA X 0.83
TAG X 0.17
TGT Cys 0.20
TGT Cys 0.80
TGA X 0.00
TGG Trp 1.00
CTT Leu 0.05
CTC Leu 0.06
CTA Leu 0.01
CTG Leu 0.83
CCT Pro 0.08
CCC Pro 0.01
CCA Pro 0.08
CCG Pro 0.82
CAT His 0.17
CAC His 0.83
CAA Gln 0.14
CAG Gln 0.86
CGT Arg 0.73
CGC Arg 0.24
CGA Arg 0.00
CGG Arg 0.01
ATT Ile 0.12
ATC Ile 0.86
ATA Ile 0.02
ATG Met 1.00
ACT Thr 0.36
ACC Thr 0.56
ACA Thr 0.02
ACG Thr 0.05
AAT Asn 0.09
AAC Asn 0.91
AAA Lys 0.81
AAG Lys 0.19
AGT Ser 0.01
AGC Ser 0.15
AGA Arg 0.02
AGG Arg 0.00
GTT Val 0.57
GTC Val 0.07
GTA Val 0.21
GTG Val 0.15
GCT Ala 0.45
GCC Ala 0.07
GCA Ala 0.28
GCG Ala 0.21
GAT Asp 0.28
GAC Asp 0.72
GAA Glu 0.83
GAG Glu 0.17
GGT Gly 0.48
GGC Gly 0.50
GGA Gly 0.00
GGG Gly 0.01
Figure 7
Structure model of inﬂuenza A RNA-dependent RNA polymerase subunit PB2
(PDB entry 3kc6; Yamada et al., 2010). The expressed construct was designed using
Gene Composer as described in this paper. The expression and puriﬁcation
methods are as described in Raymond et al. (2011). The ﬁgure was downloaded
from the PDB.Accelerated Technologies Center for Gene to Three-Dimensional
Structure.
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